A Study of PVP001, PVP002, and PVP003 in Healthy Adults and PVP001 and PVP002 in Adults With Celiac Disease

NCT03701555 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

139

Enrollment

INDUSTRY

Sponsor class

Conditions

Digestive System Disease

Interventions

OTHER: PvP001 placebo
DRUG: PvP001 100 mg
DRUG: PvP001 300 mg
DRUG: PvP001 900 mg
DRUG: Maximum Feasible Dose (MFD) of PvP002
DRUG: Maximum Tolerated Dose (MTD) of PvP001
DRUG: MTD of PvP001 following 7 days of PPI treatment
OTHER: PvP002 placebo
DRUG: PvP001 600 mg
DRUG: PvP003 placebo
DRUG: PvP003
DRUG: PvP003 150 mg

Sponsor

Millennium Pharmaceuticals, Inc.